FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Applied StemCell, Inc. Announces The Appointment Of Dr. Stanford Professor And Vice President Of To Its (SAB) March 5, 2017 2 Biotechs Insiders Just Bought $70 Million Worth of Stock In June 7, 2017 Why an Acquisition of This CAR-T Biotech Makes Sense March 9, 2017
Applied StemCell, Inc. Announces The Appointment Of Dr. Stanford Professor And Vice President Of To Its (SAB) March 5, 2017
